Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel

Cancer

Volumn 109, Issue 4, 2007, Pages 727-731

  Ceribelli, Anna ^a   Pino, Maria S ^a   Gelibter, Alain J ^a   Milella, Michele ^a   Cecere, Fabiana L ^a   Caterino, Mauro ^a   Facciolo, Francesco ^a   Mirri, Alessandra ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Nonsmall cell lung cancer; NSCLC; Sequential chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; VINDESINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 33846938334     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22480     Document Type: Article

References (21)

1. Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: the global picture. Eur J Cancer. 2001;37(Suppl 8):S4-S66.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995;311:899-909.
3. Ardizzoni A, Tiseo M, Boni L, et al. CISCA (cisplatin vs carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first line treatment of advanced non small cell lung cancer (NSCLC). Proc ASCO. 2005;24:7011.
4. Smith IE, Obrien MER, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol. 2001;19:1336-1343.
5. Socinski M, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIb/IV non-small cell lung cancer. J Clin Oncol. 2002;20:1335-1343.
6. Novello S, Bruzzi P, Barone A, et al. Phase III study in stage IV non small cell lung cancer (NSCLC) patients (pts) treated with two cycles of Cisplatin/Gemcitabine followed by a randomitazion to three additional cycles of the same combination or gemcitabine alone. Proc ASCO. 2005;23:7051.
7. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933-2939.
8. Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients. Proc ASCO. 2005;23:7143.
9. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52:155-163.
10. Edelman MJ, Gandara DR, Lau DH, et al. Sequential combination chemotherapy in patients with advanced non-small cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001;92:146-152.
11. Edelman MJ, Clark JI, Chansky K, et al. Phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004;10:5022-5026.
12. Hosoe S, Komuta K, Shibata K, et al. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer. 2003;8:342-347.
13. Gandara D, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a Phase II multicenter trial. J Clin Oncol. 2000;18:131-135.
14. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
15. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer. 1996;78:1203-1210.
16. Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32:583-587.
17. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20:859-866.
18. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003;21:3207-3213.
19. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;21:4285-4291.
20. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;2:92-98.
21. Gridelli C, Gallo C, Di Maio M, et al. A randomized clinical trial of two docetaxel regimens (weekly vs every 3 weekly) in the second-line treatment of nonsmall-cell lung cancer: the DISTAL 01 study. Br J Cancer. 2004;91:1996-2004.